Perspectives on the Future of Retinal Disease Management
Experts conclude this series highlighting what is on the horizon of retinal disease care.
EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME
EP: 2.Choosing First-Line Therapy in nAMD or DME
EP: 3.When to Switch to More Efficacious Agents
EP: 4.Real-World Experiences With Faricimab
EP: 5.Real-World Experiences With Aflibercept 8mg
EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg
EP: 7.Perspectives on Retinal Fluid Management
EP: 8.Perspectives on Loading Dose Recommendations for New Therapies
EP: 9.Safety Considerations for New Therapies
EP: 10.The Impact of Biosimilars in Retinal Diseases
EP: 11.The Status of Gene Therapy Development for Retinal Diseases
EP: 12.Considering Safety of Gene Therapy for Retinal Diseases
EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases
EP: 14.Perspectives on the Future of Retinal Disease Management
Summary
In this final segment, the participants share their excitement for the future of retina care this year and beyond. Across the panel, experts express enthusiasm for the constant evolution of therapies, techniques, and technologies in the field of retina. They touch on the ongoing trials and current research, acknowledging the challenges and complexities of developing new drugs but remains optimistic about potential breakthroughs. Experts circle back to gene therapy, emphasizing the potential for game-changing developments once challenges like inflammation are addressed. The physicians across the panel are excited at the prospect of higher durability agents to continue improving patient quality of life.
This summary was AI-generated and edited for clarity.
